325 related articles for article (PubMed ID: 30196508)
1. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
[TBL] [Abstract][Full Text] [Related]
2. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
3. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
5. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
6. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
[TBL] [Abstract][Full Text] [Related]
7. The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.
Wang Q; Wang T; Zhang R; Yang S; McFarland KS; Chung CY; Jia H; Wang LX; Cipollo JF; Betenbaugh MJ
Biotechnol Bioeng; 2022 Jan; 119(1):102-117. PubMed ID: 34647616
[TBL] [Abstract][Full Text] [Related]
8. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.
Moore GL; Chen H; Karki S; Lazar GA
MAbs; 2010; 2(2):181-9. PubMed ID: 20150767
[TBL] [Abstract][Full Text] [Related]
9. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions.
Kellner C; Derer S; Valerius T; Peipp M
Methods; 2014 Jan; 65(1):105-13. PubMed ID: 23851282
[TBL] [Abstract][Full Text] [Related]
10. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
11. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
12. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
13. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
14. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
15. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies.
Thomann M; Reckermann K; Reusch D; Prasser J; Tejada ML
Mol Immunol; 2016 May; 73():69-75. PubMed ID: 27058641
[TBL] [Abstract][Full Text] [Related]
16. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
17. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
18. Fc-engineered antibodies with immune effector functions completely abolished.
Wilkinson I; Anderson S; Fry J; Julien LA; Neville D; Qureshi O; Watts G; Hale G
PLoS One; 2021; 16(12):e0260954. PubMed ID: 34932587
[TBL] [Abstract][Full Text] [Related]
19. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
20. An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.
Wirt T; Rosskopf S; Rösner T; Eichholz KM; Kahrs A; Lutz S; Kretschmer A; Valerius T; Klausz K; Otte A; Gramatzki M; Peipp M; Kellner C
Transfus Med Hemother; 2017 Sep; 44(5):292-300. PubMed ID: 29070974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
